Delcath Systems Inc - Asset Resilience Ratio
Delcath Systems Inc (DCTH) has an Asset Resilience Ratio of 38.44% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See DCTH current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Delcath Systems Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see DCTH asset base.
Liquid Assets Composition Over Time
This chart breaks down Delcath Systems Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read DCTH liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $47.99 Million | 38.44% |
| Total Liquid Assets | $47.99 Million | 38.44% |
Asset Resilience Insights
- Very High Liquidity: Delcath Systems Inc maintains exceptional liquid asset reserves at 38.44% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Delcath Systems Inc Industry Peers by Asset Resilience Ratio
Compare Delcath Systems Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medtronic plc
SA:MDTC34 |
Medical Devices | 7.82% |
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Emvision Medical Devices Ltd
AU:EMV |
Medical Devices | 0.06% |
|
Theradiag SA
PA:ALTHE |
Medical Devices | 15.59% |
|
Biosynex
PA:ALBIO |
Medical Devices | 3.35% |
Annual Asset Resilience Ratio for Delcath Systems Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Delcath Systems Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.49% | $47.58 Million | $123.63 Million | +11.30pp |
| 2024-12-31 | 27.19% | $20.82 Million | $76.59 Million | -24.11pp |
| 2023-12-31 | 51.30% | $19.81 Million | $38.61 Million | -- |
| 2022-12-31 | 0.00% | $0.00 | $17.86 Million | -- |
| 2011-12-31 | 14.13% | $4.98 Million | $35.24 Million | +11.18pp |
| 2010-12-31 | 2.95% | $1.49 Million | $50.58 Million | +0.99pp |
| 2008-12-31 | 1.96% | $222.71K | $11.36 Million | -25.52pp |
| 2006-12-31 | 27.48% | $2.41 Million | $8.76 Million | -58.36pp |
| 2005-12-31 | 85.84% | $11.10 Million | $12.93 Million | -10.12pp |
| 2004-12-31 | 95.97% | $7.06 Million | $7.35 Million | +12.96pp |
| 2003-12-31 | 83.00% | $2.02 Million | $2.43 Million | +62.58pp |
| 2002-12-31 | 20.42% | $370.00K | $1.81 Million | -- |
About Delcath Systems Inc
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development… Read more